retatrutide safety clinical trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide—A Game Changer in Obesity

Retatrutide: Surgery-Level Results from a Triple Agonist The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lillys investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

GLP-1RA-based therapies are believed to exert antioxidant effects, protecting cells from damage and alleviating pain

short deviations are usually less concerning than prolonged warmth

During any rapid weight loss program, there is a risk of losing lean muscle mass alongside adipose tissue

This creates a 5mg/mL concentration where a 1mg starting dose requires 20 units (easy to read on any syringe) and a 2mg dose requires 40 units (clean, precise marking)

Tirzepatide has demonstrated total lean mass loss as well, although additional studies are needed to determine the impact of this [134,182]